Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Livzon Pharmaceutical Group ( (HK:1513) ).
Livzon Pharmaceutical Group’s subsidiary Livzon MABPharm has secured inclusion of its innovative biologic Lecankitug Injection in China’s priority review and approval process for marketing authorization, targeting adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. As the first domestically developed and second globally developed dual IL-17A/F inhibitor, Lecankitug demonstrated superior efficacy and a favorable safety profile versus secukinumab in a Phase III trial, underscoring the company’s strengthening position in high-value dermatology biologics and potentially accelerating time-to-market in a large, underserved psoriasis population, though regulatory and competitive uncertainties remain for investors and other stakeholders.
The most recent analyst rating on (HK:1513) stock is a Buy with a HK$32.00 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group, through its controlling subsidiary Livzon MABPharm, operates in the biopharmaceutical industry with a focus on innovative biologic therapies. The group develops monoclonal antibody drugs targeting immune-mediated diseases such as psoriasis, aiming at both the Chinese and global markets for advanced dermatology and immunology treatments.
Average Trading Volume: 742,090
Technical Sentiment Signal: Hold
Current Market Cap: HK$31.83B
For detailed information about 1513 stock, go to TipRanks’ Stock Analysis page.